Cargando…
Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer
Overcoming cisplatin (CDDP) resistance is a major issue in urothelial cancer (UC), in which CDDP‐based chemotherapy is the first‐line treatment. WEE1, a G(2)/M checkpoint kinase, confers chemoresistance in response to genotoxic agents. However, the efficacy of WEE1 blockade in UC has not been report...
Autores principales: | Murakami, Kaoru, Kita, Yuki, Sakatani, Toru, Hamada, Akihiro, Mizuno, Kei, Nakamura, Kenji, Takada, Hideaki, Matsumoto, Keiyu, Sano, Takeshi, Goto, Takayuki, Akamatsu, Shusuke, Saito, Ryoichi, Tsuruyama, Tatsuaki, Ogawa, Osamu, Kobayashi, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409401/ https://www.ncbi.nlm.nih.gov/pubmed/34212455 http://dx.doi.org/10.1111/cas.15051 |
Ejemplares similares
-
IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab
por: Sakatani, Toru, et al.
Publicado: (2022) -
Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process
por: Su, Yu-Li, et al.
Publicado: (2023) -
WEE1 inhibition enhances sensitivity to hypoxia/reoxygenation in HeLa cells
por: Goto, Tatsuaki, et al.
Publicado: (2019) -
Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies
por: Kita, Yuki, et al.
Publicado: (2019) -
Bladder urothelial carcinoma producing insulin‐like growth factor II: A case report
por: Funada, Satoshi, et al.
Publicado: (2018)